GSK's RSV drug Arexvy accepted for regulatory review in Europe
(Alliance News) - GSK PLC on Friday said its respiratory syncytial virus vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand its use in adults 18 years and older. Read More